SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions

20120121501 - Hmgn2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor... Agent: Sanford-burnham Medical Research Institute

20120121502 - Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof: The present invention relates to novel pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.... Agent: Acetylon Pharmaceuticals

20120121504 - B cell surface reactive antibodies: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Svcs.

20120121503 - Inhibition of cd69 for treatment of inflammatory conditions: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same.... Agent: National University Corporation Chiba University

20120121506 - Targeting of bone marrow neovasculature: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).... Agent:

20120121505 - Therapeutic compositions and methods: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.... Agent:

20120121507 - Peptide ligands for clusterin and uses thereof: Peptides are disclosed that are useful for molecular imaging or diagnosis of a disease state, such as cancer, in which clusterin is upregulated.... Agent:

20120121508 - Radiolabeled cgrp antagonists: The present invention is directed to radiolabeled CGRP receptor antagonists which are useful for the quantitative imaging of CGRP receptors in mammals.... Agent: Merck Sharp & Dohme Corp.

20120121509 - Vital fluorochrome conjugates and methods of use: The present invention provides compositions and methods based on vital fluorochrome conjugates that are useful for imaging dying and dead cells.... Agent: The General Hospital Corporation

20120121511 - Infection detection methods and systems and related compounds and compositions: e

20120121510 - Localized therapy following breast cancer surgery: Particles providing prolonged release of chemotherapy are injected or implanted into surgical sites in the breast following removal of cancerous tissue. In one embodiment, the particles are designed to not release formulation for approximately two to three weeks after surgery so as to not inhibit healing; in another embodiment particles... Agent:

20120121512 - Monoclonal antibodies and their use: Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human... Agent: Oregon Health & Science University

20120121514 - Needle array assembly and method for delivering therapeutic agents: A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to... Agent:

20120121513 - Platform technologies for spontaneously occurring diseases: The invention provides platform technologies for spontaneously occurring diseases that can be used for translational medicine. Non-human companion animals, such as dogs, spontaneously develop diseases that mirror human diseases. Using companion animals that develop spontaneously occurring diseases can benefit the time and cost for translational medicine by allowing for testing... Agent: Oatmeal Biotechnologies Group LLC

20120121515 - Methods and compositions for cell-proliferation-related disorders: Methods of treating and evaluating subjects having neoactive mutants are described herein.... Agent:

20120121518 - Multifunctional imaging and therapeutic nanoparticles: Multifunctional nanoparticles for imaging and therapeutic drug delivery made from amphiphilic block copolymers having a hydrophobic block and one or more hydrophilic blocks, and at least one internal and one terminal chelating agent units having a paramagnetic metal ion associated therewith.... Agent:

20120121517 - Biodegradable and thermosensitive poly(organophosphazene)-superparamagnetic nanoparticle complex, preparation method and use thereof: The present invention relates to a poly(organophosphazene)-superparamagnetic nanoparticle complex including a biodegradable and thermosensitive poly(organophosphazene) and a iron oxide (Fe3O4, Magnetite)-series ferrite superparamagnetic nanoparticle, a preparation method, and uses of carrying a physiologically-active material, a bio-material and a biomaterial for cancer hyperthermia. The iron oxide is used as a MRI... Agent: Korean Institute Of Science And Technology Of Seoul, Republic Of Korea

20120121516 - Emulsion activatable by ultrasounds and method for producing same: The invention relates to an emulsion that can be activated by ultrasounds, comprising, in an emulsion in an aqueous solution, microparticles having a diameter of less than 10 μm and containing an active agent and a gaseous precursor in a liquid form, encapsulated by a first emulsifier. The microparticles contain... Agent: Centre National De La Recherche Scientifique- Cnrs

20120121519 - Natural polymeric emulsifiers and method for use: Polymeric emulsifiers include polysaccharides modified with at least one cross-linking reagent and with from about 1 mol % to about 10 mol % of at least one ionic reagent, methods for preparing the same, and emulsions including the polymeric emulsifiers.... Agent: Akzo Nobel Chemicals International B.v.

20120121520 - Functional formulation in chewing gum: Nutraceutical gum or functional food compositions comprise Ashwagandha (Withania somnifera) and L-theanine in a sublingual formulation. Methods of making suitable sublingual formulations are described. Also provided is a method for reduction of stress and/or enhancement of energy and mental clarity, comprising administering to an individual in need thereof an effective... Agent:

20120121523 - Compositions having hase rheology modifiers: A monomer compound that contains at least one polymerizable functional group per molecule, and at least one bicycloheptyl-, bicycloheptenyl-, or branched (C5-C42)alkyl-polyether radical per molecule, wherein the bicycloheptyl- or bicycloheptenyl-polyether radical may optionally be substituted on one or more of the ring carbon atoms by one or two (C1-C6)alkyl groups... Agent: Rhodia Operations

20120121521 - Cosmetic coating to protect unclothed skin from thermal injury: A hydrogel composition and a method for protecting a surface from thermal injury is disclosed. The method comprises applying a hydrogel composition to the surface to protect the skin from exposure to a heat flux, wherein the hydrogel is of a type and applied in an amount effective to reduce... Agent: Texas Research International, Inc.

20120121522 - Metabolized conditioned growth medium and methods of use: Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used... Agent: Skinmedica, Inc.

20120121524 - Photo-stable cosmetic or dermatological compositions: m

20120121525 - Antiperspirant compositions containing triethylhexanoin:

20120121526 - Antiperspirant compositions containing triethylhexanoin: A mild reducing composition and method for straightening human hair are described. The composition contains cysteamine hydrochloride in the range of 5-10% by weight at a pH range of 7.0-9.0. The composition is applied to hair and processed for 15-45 minutes. The hair is rinsed with water, dried with a... Agent:

20120121527 - Novel biaromatic compounds that modulate ppary type receptors and cosmetic/pharmaceutical compositions comprised thereof: m

20120121529 - Hair conditioners comprising selected cationic silicones and dimethicone: Hair preparations containing selected cationic silicones and dimethicone are used for the treatment of keratin fibers, in particular human hair.... Agent: Henkel Ag & Co. Kgaa

20120121528 - Hair care agent containing acetylpyridinium salts: Cosmetic hair treatment agent free from hydrogen peroxide and/or the addition products thereof to organic and inorganic compounds and having, in a cosmetic carrier, at least one surface-active agent chosen from anionic, amphoteric and/or zwitterionic surfactants, and at least one acetylpyridinium derivative of formula (I) for improving the general condition... Agent:

20120121531 - Biocomposite for artificial tissue design: The present invention concerns a biocomposite useful in artificial tissue replacement, methods for its production, and methods of use. The biocomposite can be implanted into humans or animals as an artificial tissue for treatment of a tissue defect. The biocomposite can be formed or manipulated into a desired shape for... Agent: University Of South Florida

20120121530 - Vasoprotective and cardioprotective antidiabetic therapy: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.... Agent: Boehringer Ingelheim International Gmbh

20120121532 - Process for making dry and stable hemostatic compositions: d) finishing the final container to. a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.... Agent: Baxter International Inc.

20120121533 - Nucleic acid ligands to ll37: The present invention is directed to nucleic acid ligands to LL37, methods for producing said nucleic acid ligands, and methods for utilizing said nucleic acid ligands. In one exemplary embodiment, for example, this invention relates to nucleic acid ligands exhibiting high specific binding affinity to LL37 peptides, precursors and/or portions... Agent: Biotex, Inc.

20120121534 - Injectable composition combining a filling agent and a fibroblast growth medium: The invention relates to a composition that can be subcutaneously or intradermally injected, comprising: a filling agent; and a fibroblast growth medium.... Agent: Jean-noel Thorel

20120121535 - Agent for preventing recurrence of leukemia: The present invention provides a drug capable of initiating the progression of the cell cycle of leukemia stem cells to overcome the resistance of the leukemia stem cells to cell cycle-dependent chemotherapeutic agents, and a drug for suppressing recurrence of leukemia containing the same, and the like, an agent containing... Agent: Riken

20120121538 - Combined measles-malaria vaccine: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and... Agent: Cadila Healthcare Limited

20120121536 - Compositions and methods for glucose transport inhibition: Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis.... Agent: Ohio University

20120121537 - Methods and compositions for inhibiting hepatitis c virus replication: Compositions and methods for reducing hepatitis C virus (HCV) replication are provided. Also provided are compositions and methods of treating an HCV infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral... Agent:

20120121539 - Programming of cells for tolerogenic therapies: Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.... Agent: President And Fellows Of Harvard College

20120121540 - Certain nitrogen containing bicyclic chemical entities for treating viral infections: Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).... Agent:

20120121541 - 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof: The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective... Agent: Anadys Pharmaceuticals, Inc.

20120121542 - Red-shifted opsin molecules and uses thereof: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the use of light-activated ion pumps (LAIPs).... Agent:

20120121543 - Anti-microbial agent from paenibacillus sp. and methods and uses thereof: The present invention provides, in part, a Paenibacillus sp. isolate, designated Paenibacillus polymyxa JB05-01-1, as well as an anti-microbial agent obtained from the bacterium or cell culture supernatant thereof. Compositions, methods and uses are also provided.... Agent: Best Environmental Technologies Inc.

20120121558 - Compositions and methods for treating plasma protein deficiency disorders: The disclosure of the present application provides compositions and methods for treating a blood disorder. In at least one embodiment of a method for treating a patient with a plasma protein deficiency disorder, the method comprises the steps of administering a cell-based composition to a patient with a plasma protein... Agent:

20120121560 - Methods of expanding and redifferentiating islet beta cells: A method of ex-vivo increasing insulin content in progenitor cells which express SLUG is provided. The method comprises downregulating an amount or activity of SLUG in the progenitor cells. Cell populations generated thereby and uses thereof are also provided.... Agent:

20120121559 - Treatment and prevention of pathological conditions using iduna related techniques and compositions: Research into neuroprotective mechanisms has at its heart the goal of developing new therapeutic strategies to treat patients. For example, the compositions and induction strategies disclosed herein have use for acute injuries such as stroke or trauma, and would be extremely useful in treating patients undergoing cardiac bypass surgery, neurosurgery... Agent:

20120121561 - Dry whole milk preparations containing probiotic micro-organisms: The present invention relates to the field of nutrition for young children. In particular, the present invention relates to dry whole milk preparations comprising probiotic micro-organisms to be administered to young children older than 12 months. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic... Agent: Nestec S.a.

20120121562 - Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients: The present invention relates to a nutritional supplement compositions for breast-fed infants or pets which comprise at least one probiotic and at least one nutrient. The compositions are aimed at preserving exclusive breast feeding in infants. The compositions of the invention are also for use in improving the health of... Agent: Nestec S.a.

20120121563 - Specialized nutritional formula for adult patients with gastrointestinal intolerance containing probiotics: The present invention relates to the field of nutrition for adults. In particular, the present invention relates to the nutritional compositions intended for adults with an impaired function of the gastro-intestinal tract. One embodiment of the present invention relates to a nutritional composition to be administered to adults with an... Agent: Nestec S.a.

20120121564 - Use of selected lactic acid bacteria for reducing infantile colic: The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.... Agent: Biogaia Ab

20120121565 - Protein recovery: A process for recovering a protein-containing fermentation agent, comprising (i) forming an aqueous mixture of an organic material and a protein-containing fermentation agent capable of fermenting the organic material to produce ethanol, (ii) fermenting the aqueous mixture to produce ethanol, (iii) recovering from the fermented aqueous mixture an ethanol stream... Agent: Ab Agri Limited

20120121551 - Compositions and methods for immunostimulatory rna oligonucleotides: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-α-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for... Agent:

20120121555 - Compositions and methods of using living and non-living bioactive devices with components derived from self-renewing colony forming cells cultured and expanded in vitro: The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone... Agent: Garnet Biotherapeutics, Inc.

20120121554 - Hmg-coa secondary metabolites and uses thereof: The present invention is directed, among other things, to using secondary metabolites in the mevalonate pathway (such as, for example, HMG) and/or structurally related compounds to mediate biological activities (e.g., for therapeutic applications) and/or as diagnostic agents. In some embodiments, the biological activities comprise one or more pleiotropic effects of... Agent: Edenspace Systems Corporation

20120121549 - Induced pluripotent stem cells and methods of use: The invention relates to the field of stem cells and, specially, to the reprogramming of adult somatic cells; to obtain pluripotent cells by the transfection of specific genes. Thus, the invention provides induced pluripotent stem cells (iPS) and methods of obtaining and using them.... Agent: Salk Institute For Biological Studies

20120121544 - Method for efficiently proliferating and differentiating natural killer cells from umbilical cord blood: The present invention relates to a method for efficiently proliferating and differentiating natural killer cells (NK cells) from umbilical cord blood, more precisely a method for efficiently proliferating and differentiating natural killer cells from umbilical cord blood comprising the following steps: 1) preparing CD3 negative cells by eliminating CD3 positive... Agent: Medicell Corporation

20120121546 - Method of producing progenitor cells from differentiated cells: The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and/or tissue or organ repair and/or regeneration and/or building are also provides. Methods of using progenitor... Agent:

20120121547 - Methods and compositions for treating chronic wounds: The invention is directed to novel methods for treating wounds, in particular, chronic wounds such as diabetic ulcers. Such methods utilize novel cell and cell-product compositions in combination with insulin.... Agent:

20120121552 - Methods for purifying hematopoietic stem cells: Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells.... Agent: Children's Medical Center Corporation

20120121556 - Methods of using regenerative cells to promote wound healing: Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the... Agent: Cytori Therapeutics, Inc.

20120121557 - Neuregulin induced proliferation of cardiomyocytes: The present invention provides methods for inducing division of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to repair heart tissue damaged by, for example, myocardial ischemia, hypoxia, stroke, myocardial infarction or chronic ischemic heart disease in vivo. In addition, the methods of the invention can be used to... Agent: Children's Medical Center Corporation

20120121545 - Pharmaceutical composition for bone disease treatment or countering inflammation, comprising cartilage stem cells as an active principle: Disclosed is a pharmaceutical composition for treating bone disease or countering inflammation containing cartilage stem cells as an active ingredient. The present disclosure provides a novel cell treatment regimen for bone disease and inflammatory disease using the cartilage stem cells as an active ingredient. When the cartilage stem cells of... Agent: Corestem Co., Ltd.

20120121550 - Production of oligodendrocytes from placenta-derived stem cells: The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system... Agent:

20120121548 - Production of reprogrammed pluripotent cells: The present invention provides a method of producing a reprogrammed cell, said method comprising exposing Stro-1+ multipotential cells and/or progeny cells thereof to one or more potency-determining factors under conditions sufficient to reprogram the cells. The present invention also provides cells produced by such a method and cells differentiated therefrom... Agent:

20120121553 - Selection and propagation of progenitor cells: A population of progenitor cells and methods for obtaining and culturing the progenitor cells, that are useful in fields including regenerative medicine (tissue regeneration), transplantation, and cancer research.... Agent: Organ Recovery Systems, Inc.

20120121567 - Ophthalmic solution for protecting internal structures of the eyeball against uv-a rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique: An ophthalmic solution containing riboflavin and at least a compound chosen in the group composed of essential and conditionally essential amino acids, coenzyme Q, L-proline, glycine, lysine hydrochloride, L-leucine, L-arginine and compounds intended to stimulate the production of metalloproteinase MMP9 for the protection of internal structures of the eyeball against... Agent:

20120121566 - Solubilized coq-10: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.... Agent: Soft Gel Technologies, Inc.

20120121568 - Superoxide dismutase variants and methods of use thereof: The present disclosure provides variant superoxide dismutase polypeptides, compositions comprising the polypeptides, and nucleic acids comprising nucleotide sequences encoding the polypeptides. The present disclosure provides methods of reducing oxidative damage in a cell, tissue, or organ. The present disclosure provides methods of identifying agents that increase superoxide dismutase activity.... Agent:

20120121571 - Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus... Agent: The Regents Of The University Of Michigan

20120121569 - Methods of treating infections originating from viruses in the herpesviridae family: Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.... Agent: Tamir Biotechnology, Inc.

20120121570 - Test for predicting neutralization of asparaginase activity: Method of in vitro measurement of the presence of factors that are able to neutralize asparaginase activity in a sample of blood, plasma, serum or derived medium that may contain asparaginase neutralizing factors, obtained from a patient, comprising mixing of said sample with asparaginase, incubation of said mixture, then measurement... Agent:

20120121572 - New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of... Agent: Fidia Farmaceutici S.p.a.

20120121573 - Treatment of pulmonary vascular remodeling with neprilysin: The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.... Agent:

20120121576 - Actriia binding agents and uses thereof: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same.... Agent:

20120121577 - Antibodies as t cell receptor mimics, methods of production and uses thereof: Antibodies are produced that recognize peptides displayed in the context of MHC molecules and thus mimic the specificity of a T cell receptor (TCR). The antibodies are produced by immunizing a host with at least one peptide/MHC complex to elicit an immune response thereto. The desired antibodies can differentiate the... Agent:

20120121574 - Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore: Polypeptides derived from constant domains of antibody light (L) and/or heavy (H) chains as well as from complementary determining regions (CDRs) of immunoglobulin variable regions are disclosed possessing broad spectrum biological activities including, among others, antifungal, antibacterial, antiviral, anticancer and/or immunomodulatory activity in vitro, ex vivo and/or in vivo.... Agent:

20120121580 - Methods for producing high concentration lyophilized pharmaceutical formulations: The present invention relates to methods of producing lyophilized pharmaceutical compositions comprising a high concentration of therapeutic protein or antibody prior to lyophilization, wherein the lyophilized formulation can be reconstituted with a diluent in about 15 minutes or less. The invention also relates to the high concentration lyophilized formulations produced... Agent: Merck Sharp & Dohme Corp.

20120121578 - Methods of using immunoglobulin aggregates: The current invention provides a method of treating a mammal in need of such treatment with aggregated IgG derived from pooled human plasma. The invention further provides using the discarded fraction obtained during the course of standard IgG fractionation as the source of the aggregated IgG. The methods of the... Agent: Gliknik Inc.

20120121575 - Prohibitin as target for cancer therapy: The present invention relates to pharmaceutical compositions comprising inhibitors of Prohibitin (PHB) for the prevention or/and treatment of hyperproliferative disorders.... Agent: Dr. Thomas Rudel

20120121579 - Treatment of oncostatin m receptor beta mediated heart failure: The present invention relates to an inhibitor of the oncostatin M receptor β or an inhibitor of an activator of the oncostatin M receptor β for use in the treatment and/or prevention of heart failure. The present invention also relates to a method of treating and/or preventing heart failure comprising... Agent: Max-planck-gesellschaft Zur Forderung Der Wissenschaften E.v.

20120121587 - Anti-axl antibody: An objective of the present invention is to decrease the immunogenicity of mouse-derived anti-AXL antibodies in humans by humanizing them. The present invention provides antibodies that can bind to a specific region in Anexelekto (AXL) and humanized antibodies that are produced based on such antibodies. The anti-AXL antibodies of the... Agent: Chugai Seiyaku Kabushiki Kaisha

20120121581 - Anti-botulism antibody coformulations: This invention relates to stable formulations of multiple antibodies comprising a plurality of anti-botulism antibodies and an effective amount of a succinate buffer, an effective amount of arginine, wherein the antibodies are present in substantially equal concentrations and the pH of the formulation is between about 5 and about 6.5.... Agent: Xoma Technology Ltd.

20120121583 - Antibodies against human tweak and uses thereof: The invention provides antibodies binding to TWEAK, including anti-TWEAK antibodies comprising a heavy chain variable domain CDR3 (CDR3H) selected from the group consisting of SEQ ID NO: 8, 16 or 24. The invention provides anti-TWEAK antibodies which are useful for the treatment of cancer, autoimmune diseases, rheumatoid arthritis, psoratic arthritis,... Agent: Genentech, Inc.

20120121589 - Modified egfr ectodomain: A protein that attenuates EGFR and/or EGFR family members comprises a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a portion of the EGFR (or EGFR family member) and the “U” region epitope of EGFR related protein (ERRP), wherein the portion... Agent: Wayne State University

20120121588 - Modulation of pilr receptors to treat sepsis: The present invention provides methods of using agonists and antagonists of PILRα and PILRβ, respectively, to treat immune mediated sepsis. Also provided are methods of prophylactically treating with agonists and antagonists of PILRα and PILRβ respectively, to prevent the development of sepsis.... Agent: Schering Corporation

20120121586 - Modulators for her2 signaling in her2 expressing patients with gastric cancer: The present invention relates to means and methods for the identification of responders for or a patient sensitive to a modulator of the HER2/neu (ErbB2) signaling pathway. Also described herein are corresponding methods of treatment of a group of patients determined and defined in accordance with the identification method of... Agent:

20120121582 - Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of... Agent: Medimmune, LLC

20120121584 - Monoclonal antibodies against extracellular loops of c5ar: The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a... Agent:

20120121585 - Silent fc variants of anti-cd40 antibodies: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.... Agent: Novartis Ag

20120121594 - Anti-il-6 antibodies for the treatment of arthritis: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.... Agent: Alder Biopharmaceuticals, Inc.

20120121593 - Method for determining predisposition to pulmonary infection: Provided herein are methods and materials for diagnosing a subject's predisposition for pulmonary infection in a CF subject by detecting a pulmonary infection genetic marker. Pulmonary infection markers have been identified in the IL-1 gene cluster and may be useful in predicting CF disease progression and assessing a CF subject's... Agent:

20120121590 - Methods of inhibiting adverse cardiac events and treating atherosclerosis and coronary artery disease using galectin-3 binding protein (gal-3bp, btbd17b, mac-2 binding protein): The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide sequences and compositions that include Gal-3BP polypeptide sequences, and methods of using Gal-3BP polypeptide sequences, including modified forms and wild type (native) forms of Gal-3BP polypeptide, such as in treatment, diagnostic, detection and prognostic methods.... Agent:

20120121591 - Selective and potent peptide inhibitors of kv1.3: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a... Agent: Amgen Inc.

20120121592 - Targeting antigens to human dendritic cells via dc-asialoglycoprotein receptor to produce il-10 regulatory t-cells: Compositions and methods for targeting protein antigens to human DCs via DC-asialoglycoprotein receptor (DC-ASGPR) are disclosed herein. The DC-ASGPR carries an intracellular tyrosine-based and dileucine motif, resulting in the generation of such IL-10 Tregs both in vitro and in vivo. The methods of the present invention can be used for... Agent: Baylor Research Institute

20120121595 - Fragment of secreted heat shock protein-90alpha (hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors: The invention provides methods for treating HIF-1α-overexpressing human tumors, inhibiting HIF-1α-overexpressing tumor invasion and preventing tumor metastasis, and/or promoting tumor prophylaxis, using various types of inhibitors against the Hsp90α from the tumors.... Agent: University Of Southern California

20120121596 - Bispecific anti-her antibodies: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.... Agent:

20120121599 - Compositions and methods for stem cell delivery: This invention provides compositions of matter, articles of manufacture and methods for delivering and/or affixing a stem cell to a target tissue. This invention also provides related nucleic acids, vectors, cells, methods of production, and kits.... Agent:

20120121598 - Compositions containing antibodies for treating cd5+hla-dr+b or t cell related diseases: The present invention relates to compositions containing antibodies for treating CD5+ HLA-DR+ B OR T cell related diseases such as B or T cell malignances (leukaemia and lymphoma), autoimmune diseases and T cell related diseases as transplantation and graft rejection.... Agent:

20120121597 - Fusion proteins for hiv therapy: Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral... Agent: The Rockefeller University

20120121600 - Pharmaceutical antibody compositions with resistance to soluble cea: The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” and... Agent: Micromet Ag

20120121601 - Mammalian receptor proteins; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.... Agent: Schering Corporation

20120121602 - Novel proteins: Provided herein are four polypeptides, named PRT5, PRT6, PRT7 and PRT8, the nucleic acids encoding the same, compositions comprising the proteins, as well as their uses in therapeutic and diagnostic methods. Antibodies which specifically recognize the polypeptides are also provided, as well as their uses. Characterization of each protein showed... Agent: Two To Biotech Ltd.

20120121604 - Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. Such Compositions comprise inter alia an anti-CTLA-4 agent, e.g. ipilimumab or tremelimumab in combination with other chemotherapeutic agents such as dasatinib, imatinib, paclitaxel, gemcitabine, cisplatin or etoposide.... Agent: Bristol-myers Squibb Company

20120121603 - Compositions and methods for the therapy and diagnosis of influenza: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.... Agent: Theraclone Sciences, Inc.

20120121605 - Anti sulfatides and anti sufated proteoglycans antibodies and their use: Accordingly, the invention provides pharmaceutical compositions comprising MAbs of the invention or fragments thereof for the therapeutic and diagnostic use associated with cardiovascular diseases. Particularly, the present invention relates to the fragments derived from the MAbs that recognize sulfatides and sulfated proteoglycans, which can be used in the therapy or... Agent: Centro De Inmunologia Molecular

20120121606 - Antibodies that immunospecifically bind to b lymphocyte stimulator protein: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or... Agent: Human Genome Sciences, Inc.

20120121607 - Antibodies to clostridium difficile toxins: The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin.... Agent: Health Protection Agency

20120121609 - Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (EGFR)-1(IIIb), EGFR-1(IIIc), and/or EGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing EGFR-1 or EGFR-4... Agent: Imclone LLC

20120121610 - Therapeutic agent and assay: The present invention relates to an agent that is useful in the treatment of a cell proliferative disease or disorder, and an assay for identifying such an agent.... Agent:

20120121608 - Use of sam68 for modulating signaling through the tnf receptor: Sam68 plays a role in TNF-dependent signaling, including NF-kB signaling and extrinsic activation of apoptosis. In some embodiments, inhibitors of Sam68 are administered to inhibit TNF-dependent signaling, for example to inhibit NF-kB signaling or apoptosis in a patient in need. In some embodiments, functional Sam68 is administered to increase TNF-dependent... Agent:

20120121611 - Method of treating autoimmune disease with mesenchymal stem cells: Methods and compositions for treating an autoimmune disease, such as new onset type 1 diabetes (T1D) in a subject using autologous or allogeneic mesenchymal stem cells administered to the subject prior to autoimmune-induced complete depletion of insulin-producing pancreatic beta cells, e.g., within six months of new onset type 1 diabetes... Agent: Genzyme Corporation

20120121612 - Fermented wheat germ proteins (fwgp) for the treatment of cancer: The present invention provides compositions comprising the component of fermented wheat germ extract (“FWGE”) active in reducing, inhibiting or preventing the proliferation of cancer cells and/or tumors, and methods of making and using such compositions. The active component from FWGE comprises polypeptides having a molecular weight in the range of... Agent: Regents Of The University Of California

20120121614 - Methods and compositions for bi-specific targeting of cd19/cd22: Methods and composition involving genetically engineered targeting conjugates with reversed orientation of VL and VH chains are provided. For example, in certain aspects targeting conjugates comprising VL and VH chains of anti-CD22 and anti-CD19 are described. In a further aspect, the invention provides methods and targeting conjugates comprising therapeutic agents... Agent: Daniel A. Vallera

20120121613 - Protein conjugate having an endopeptidase- cleavable bioprotective moiety: The invention is directed to a procoagulant conjugate having an endopeptidase-activatable procoagulant protein moiety and one or more bioprotective moieties, which are conjugated to one another by a linker that is cleaved by an endopeptidase in situ to release the bioprotective moiety. The invention is also directed to therapeutic uses... Agent: Bayer Healthcare LLC

20120121615 - Alaninyl maytansinol antibody conjugates: e

20120121620 - Anti-estrogen and immune modulator combinations for treating breast cancer: Compositions for treating cancers of mucosal tissues including breast, prostate, ovary, colon are disclosed which include various combinations of new or conventional anti-estrogen compounds, aromatase inhibitors, immune modulators, immune inhibitors, immune inhibitor mimicking compounds and steroid or thyroid hormones. Methods of predicting susceptibility of a cancer of mucosal origin to... Agent:

20120121622 - Biodegradable immunomodulatory formulations and methods for use thereof: The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier.... Agent: Dynavax Technologies Corporation

20120121619 - Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of determining whether the human subject is a glatiramer acetate responder by evaluating a biomarker... Agent:

20120121624 - Hepatitis c virus ns3 protease inhibitors: The present invention relates to macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent: Merck Sharp & Dohme Corp

20120121616 - Immune balance-regulating agent: Disclosed is a novel use of superheated stream-treated material. Disclosed is an immune balance-regulating agent comprising a superheated steam-treated product of crown daisy (Chrysanthemum coronarium). This immune balance-regulating agent, which comprises, as the active ingredient, a superheated stream-treated product of crown daisy that has been used as a food for... Agent:

20120121623 - Novel antipathogenic peptides: The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess... Agent: Spiderbiotch S.r.l.

20120121618 - Predicting and treating prostate cancer: The disclosure features methods and compositions for determining whether a male subject has, or is at an increased risk of developing, an aggressive form of prostate cancer. The disclosure also features methods for adjusting a treatment regimen (e.g., discontinuing a therapy comprising an antioxidant) or administering a therapy that does... Agent: Dana-farber Cancer Institute, Inc.

20120121617 - Promoters for recombinant viral expression: The invention relates to a promoter selected from a group of nucleic acids consisting of (a) a nucleic acid having the nucleotide sequence of SEQ ID NO:1; (b) a nucleic acid having a nucleotide sequence derived from SEQ ID NO:1, wherein not more than 10 nucleotides have been added, deleted,... Agent: Bavarian Nordic A/s

20120121621 - Synergistic prebiotic compositions: The invention relates to synergistic compositions comprising prebiotic components selected from fructose polymers GFn and Fm, either containing a glucose (G) end-group, or without a glucose end-group, and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed inulin,... Agent:

20120121626 - Chimeric vegf peptides: Compositions for and methods of treating patients with malignancies associated with overexpression of VEGF, particularly ovarian cancer are provided herein. The compositions include but are not limited to certain VEGF epitopes, multivalent peptides comprising the epitopes, and chimeric peptides comprising one or more of the epitopes and a T cell... Agent: The Ohio State University Research Foundation

20120121625 - Peptide: The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence... Agent: Apitope Technology (bristol) Limited

20120121627 - Peptides for active anti-cytokine immunization: Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said... Agent: Vaxconsulting

20120121628 - Lipidated polyepitope vaccines: This invention relates to, inter alia, an isolated lipidated polypeptide including a lipid moiety at the N-terminus and a plurality of epitopes, and methods of making and using the polypeptide.... Agent: National Health Research Institutes

20120121629 - New human rotavirus vaccine strains and diagnostics: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an... Agent:

20120121630 - Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast: The present invention provides Herpes Simplex Virus (HSV) gD, gC, gB and/or gE recombinant glycoproteins having a particular pre-selected N-linked glycosylation pattern as the predominant N-glycoform. The present invention also provides methods of producing these recombinant glycoproteins in yeast, preferably Pichia pastoris, which may be glycoengineered to provide particular glycosylation... Agent:

20120121635 - Expression in plants of hiv-related proteins: Plants are engineered to express HIV related surface protein genes. The plants can be used as a source of the protein for a variety of purposes. Plant tissue can be orally administered to animals to elicit an immune response or provide protection from viral infection. The protein can be extracted... Agent: Prodigene, Inc.

20120121633 - Hiv cd4 binding site based covalent immunogen compositions: Provided are immunogenic compositions based on the highly conserved, core CD4 binding site of the gp120 protein of the human immunodeficiency virus. One embodiment includes an antigenic conjugate of an electophilic derivative of HIV gp120 peptide 416-433, designated E-416-433, covalently linked to an immunogenic carrier protein. The compositions are effective... Agent:

20120121631 - Polyvalent vaccine: The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens... Agent: Duke University

20120121634 - Soluble pd-1 variants, fusion constructs, and uses thereof: The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is... Agent: The University Of Hong Kong

20120121632 - Tat protein for preventing or treating aids: The invention relates to a method of preventing or treating acquired immunodeficiency syndrome (AIDS) in a patient, wherein the patient is administered with a Tat protein comprising amino acid sequence SEQ ID NO: 1 or 2, or a variant thereof capable of stimulating an immune response against Tat proteins.... Agent: Universite De La Mediterrannee

20120121636 - Tat-based vaccine compositions and methods of making and using same: A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule wherein the antigen is a cancer antigen an infectious disease antigen or a fragment thereof and methods to treat disease by administering the Tat-based vaccine composition. An additional Tat-based... Agent: Nanirx, Inc.

20120121637 - Chimeric factor h binding proteins (fhbp) and methods of use: Chimeric fHbps that can elicit antibodies that are bactericidal for different fHbp variant strains of N. meningitidis, and methods of use, are provided.... Agent:

20120121638 - Polypeptide derived from enterococcus and its use for vaccination: A medicament for the treatment or the prevention of a bacterial infection is disclosed which contains a polypeptide having a contiguous sequence of at least six amino acids of SEQ ID NO:1. Said polypeptide can be used for the preparation of a vaccine against an Enterococcus infection.... Agent:

20120121639 - Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3... Agent: The Regents Of The University Of California

20120121640 - Ox40/trail fusion proteins: Fusion proteins which act on the OX40/TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, and alloimmune diseases, as well as cancer.... Agent: The Trustees Of The University Of Pennsylvania

20120121641 - Mhc oligomer and method of making the same: The invention discloses MHC oligomers and methods for making the same comprising at least two functional MHC complexes having a peptide binding groove, each MHC complex having a peptide bound in the peptide binding groove of the MHC complex, wherein each peptide has a modification which allows highly specific oligomerisation... Agent:

20120121642 - Anti-inflammatory hydrolysate of c. versicolor: Methods and compositions for reducing and/or inhibiting inflammation by topical application of dermatocosmetic compositions comprising effective amounts of extracts of Coriolus versicolor that have been hydrolyzed by an acid protease, preferably Rhizomucor miehei, and thereafter rendered substantially devoid of acid-protease activity.... Agent: Active Organics, Inc.

20120121643 - Engineered listeria and methods of use thereof: The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.... Agent:

20120121644 - Sticky soft gel for treating poultry: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling... Agent:

20120121645 - Supralingual vaccines and applicators: Solid and semi-solid formulations are used for supralingual administration of vaccines to animals. The formulations, which comprise antigens dispersed in a solid or semi-solid matrix, or paste, are delivered via supralingual applicators. The supralingual applicators are designed so as to position the antigen-containing matrix directly on the dorsal surface of... Agent: The Board Of Regents For Oklahoma State University

20120121646 - Vaccine: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner... Agent: Isis Innovation Limited

20120121647 - Influenza vaccine, composition, and methods of use: The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal... Agent: Institut Pasteur De Lille

20120121648 - Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles: Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated... Agent: Coley Pharmaceutical Gmbh

20120121649 - Compositions and methods for the prevention and treatment of cancer: Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens... Agent: Uti Limited Partnership

20120121650 - Chimeric virus vaccines: The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an... Agent:

20120121651 - Pyrazolopyridines and analogs thereof: Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.... Agent: 3m Innovative Properties Company

20120121652 - Complete liquid nutrition for children at the age of 1-10 years comprising probiotics: The present invention relates to the field of nutrition for children. In particular, the present invention relates to the nutritional compositions intended for children with an impaired function of the gastro-intestinal tract. One embodiment of the present invention relates to a nutritional composition to be administered to children with an... Agent: Nestec S.a.

20120121660 - Bone void fillers: A bone void filler composition is described containing an acidic mineral component that contains a calcium source and a phosphate source or a lower alkyl carboxylate source; an osteoinductive component that contains demineralized bone; and a three-dimensional, osteoconductive biologically acceptable carrier component that contains a collagenous material. The bone void... Agent: Zimmer Orthobiologics, Inc.

20120121668 - Compositions for oral adminstration of active principles requiring masking of taste: A process for the preparation of a composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of... Agent: Aventis Pharma S.a.

20120121666 - Compositions of particles: Method of making particle compositions exhibiting improved floodability and/or flowability properties. The compositions generally contain particles and non-surface modified nanoparticles.... Agent: 3m Innovative Properties Company

20120121661 - Devices with multiple surface functionality: Phosphorus-based coatings having a plurality of phosphate moieties, a plurality of phosphonate moieties, or both, covalently bonded to an oxide surface of an implantable substrate exhibiting one or more of the following characteristics: (a) the surface phosphorus-containing group density of the coated regions of the substrate is at least about... Agent: The Trustees Of Princeton University

20120121657 - Enhancing biocompatibility of a medical device: The present invention relates to a medical device comprising both pyrolytic carbon and an NO generator, methods of making same, and methods of using same.... Agent: St. Jude Medical, Inc.

20120121658 - Functionalized rgd peptidomimetics and their manufacture, and implant having a coating containing such functionalized rgd peptidomimetics: At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method.... Agent: Biotronik Ag

20120121659 - Functionalized rgd peptidomimetics and their manufacture, and implant having a coating containing such functionalized rgd peptidomimetics: At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method.... Agent: Biotronik Ag

20120121664 - Gastric acid secretion inhibiting composition: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in... Agent: Orexo Ab

20120121665 - Implantable or insertable medical device resistant to microbial growth and biofilm formation: Disclosed are implantable or insertable medical devices that provide resistance to microbial growth on and in the environment of the device and resistance to microbial adhesion and biofilm formation on the device. In particular, the invention discloses implantable or insertable medical devices that comprise at least one biocompatible matrix polymer... Agent: Boston Scientific Scimed, Inc.

20120121656 - Methods and compositions for protecting against neurotoxicity of a neurotoxic agent, and improving motor coordination associated with a neurodegenerative condition or disease: Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject... Agent: Revalesio Corporation

20120121654 - Nanoparticle isoflavone compositions & methods of making and using the same: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.... Agent: Humanetics Corporation

20120121653 - Novel mometasone compositions and methods of making and using the same: The present invention is directed to mometasone furoate compositions comprising mometasone furoate and at least one surface stabilizer. The mometasone furoate particles of the composition preferably have an effective average particle size of less than about 2000 nm.... Agent: Elan Pharma International Limited

20120121667 - Pharmaceutical composition: Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the... Agent: Alpharma Pharmaceuticals, LLC

20120121662 - Treatment using dantrolene: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of... Agent: Lyotropic Therapeutics, Inc.

20120121663 - Treatment using dantrolene: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of... Agent: Lyotropic Therapeutics, Inc.

20120121655 - Chewable formulation comprising alginate, bicarbonate and carbonate: The present invention relates to a solid, ingestible composition comprising: a) an alginate; b) a bicarbonate; and c) a carbonate wherein the composition is in the form of a chewable core, a process for preparing said composition, and its use in the treatment of reflux oesophagitis, gastritis, dyspepsia or peptic... Agent: Reckitt Benckiser Healthcare (uk) Limited

20120121675 - Compounds which inhibit muscle contraction: Peptides of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp—Zs—R2 their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, their preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases that are a consequence of muscle contraction.... Agent: Lipotec, S.a.

20120121671 - Control of fluid migration in non-latex bonded wet-wipes: The present invention describes wet-wipe composition with a liquid portion that is impregnated in a substrate, wherein the liquid portion contains a thickening or gelling polymer along with a thickening or gelling agent which substantially reduces fluid migration of the liquid portion within a wet-wipes stack during storage wherein the... Agent: Hercules Incorporated

20120121677 - Fragrance-containing compositions: An antiperspirant or deodorant composition comprising i) an antiperspirant or deodorant active, ii) a liquid carrier for the antiperspirant or deodorant active, and iii) fragrance in which the fragrance comprises a mixture of first and second fragrances, respectively (iiia) and (iiib), the first fragrance (iiia) being free from encapsulation and... Agent:

20120121676 - Method for manufacturing capsules, resulting capsules, and use of said capsules: The invention relates to a one-step process for manufacturing capsules from 1 to 100 microns with a polydispersity index of less than 10%, to suspensions of capsules obtained via this process, and to the use of these suspensions of capsules.... Agent: Centre National De La Recherche Scientifique

20120121674 - Nonwoven fabric products with enhanced transfer properties: The present invention relates to the field of non-woven textile products, and is applied to the manufacture of non-woven fabric products or generally nonwovens for various applications such as household use and personal care. In particular, the present invention relates to a wet nonwoven fabric product impregnated with a substance... Agent:

20120121669 - Oral care composition comprising capsules: Oral care compositions comprising a capsules comprising flavoring and/or one or more active ingredients, and/or flavours, said capsules distributed in an orally acceptable vehicle or carrier.... Agent: Colgate-palmolive Company

20120121672 - Particles that disrupt or impede bacterial adhesion, related compositions and methods: Oral care and other compositions comprising particles having cores attached to bioadhesive polymers for inhibition of pellicle formation, plaque formation, biofilm formation, biofouling, and microbial adhesion or attachment are described. Methods using said compositions to treat surfaces, such as oral surfaces.... Agent: Colgate-palmolive Company

20120121670 - Polyarginine nanocapsules: The present invention relates to a system for administering active ingredients comprising nanocapsules with a diameter less than 1 μm comprising a polyarginine salt, a negative phospholipid and an oil. The invention also relates to methods for obtaining said nanocapsule system, the pharmaceutical and cosmetic compositions thereof, as well as... Agent:

20120121673 - Topical compositions comprising inorganic particulates and an alkoxylated diphenylacrylate compound: A topical composition of improved spreadability and aesthetical appeal is provided, which contains inorganic particulates in combination with an alkoxylated diphenylacrylate compound. Preferably, the topical composition is a sunscreen composition that contains inorganic or physical sunscreen agents in combination with an alkoxylated α-cyanodiphenylacrylate compound, which is characterized by improved photo-protection... Agent:

20120121678 - Vapor-phase application of spinosyn for the control of pest, and formulations and products utilizing the same: The present invention relates to the vapor-phase application of at least one spinosyn to treat pests including, for example, vadult mosquitoes and houseflies.... Agent: Entarco Sa

20120121679 - Viricidal and microbicidal compositions and uses thereof: The present disclosure encompasses compositions comprising a surfactant, and an acid such as, but not limited to, levulinic acid, that together have a synergistic effect in reducing the viability of a virus population compared to the efficacy of the individual compounds. This synergy allows the formulation of compositions where the... Agent: University Of Georgia Research Foundation, Inc.

20120121680 - Animal repelling deicer: Deicing products designed to deter ungulates are provided, along with methods of using those products to treat iced surfaces. The deicing product comprises a mixture of a deicer along with an ungulate repellent. The repellent can repel based on conditioned avoidance, fear, chemical irritation, and/or bad taste. The deicer can... Agent: North American Salt Company

20120121681 - Insecticidal polymer matrix comprising pbo and dm: An insecticidal polymer matrix containing Piperonyl Butoxide (PBO) and deltamethrin (DM), wherein the ratio between the content of PBO and the content of DM in terms of weight is higher than 3.... Agent: Vestergaard Frandsen Sa

20120121682 - Crgd peptide derivative and its manufacture, and implant having a coating containing a crgd peptide derivative:

20120121684 - coating comprising a poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network: Implantable medical devices are disclosed. The devices comprise a coating comprising an interpenetrating network or semi-interpenetrating network. The interpenetrating network or semi-interpenetrating network comprises poly(ethylene glycol) and an aliphatic polyester copolymer. A method of using the implantable device is also provided.... Agent: Abbott Cardiovascular Systems Inc.

20120121683 - Functional nanoparticle filled nanotubes and methods of their production: Carbon nanotubes with a suspension or colloidal solution of functional nanoparticles and methods for production of carbon nanotubes loaded with functional nanoparticles are provided.... Agent: Drexel University

20120121685 - Breakfast cereals containing probiotic micro organisms: The present invention relates to the field of nutrition. In particular, the present invention relates to a breakfast cereal composition comprising probiotic micro-organisms. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example.... Agent: Nestec S.a.

20120121686 - Biodegradable compositions having pressure sensitive adhesive properties: A composition comprising the reaction product of (a) an isocyanate group-containing component having an average functionality of at least 2; and (b) an active hydrogen group-containing component having an average functionality of at least 2. The composition is biodegradable, a solid at 22° C. and below, and has pressure sensitive... Agent: Cohera Medical, Inc.

20120121687 - Wound healing material and method for fabricating the same: The present invention provides a wound healing material and method for fabricating the same. The wound healing material comprises a hydrophobic fluoro-containing membrane having a first surface and a second surface opposing to each other; and at least one biocompatible polymer covalently bonded to at least one part of the... Agent: Chung Yuan Christian University

20120121695 - Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylethanolamine: Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their pay-load upon exposure to acoustic energy.... Agent: Epitarget As

20120121694 - Compositions and kits for ocular treatment: Embodiments of the invention provide eyelid preparations, methods, and kits, for treating ocular conditions. The eyelid preparations comprise a mixture of tea tree oil and sea buckthorn oil in a pharmaceutically acceptable carrier.... Agent: Ocusoft Inc.

20120121697 - Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease: Compositions and methods are disclosed for the treatment and diagnosis of inflammatory diseases and disorders, including pulmonary diseases and fibrotic disorders, including COPD.... Agent:

20120121692 - Compounds and compositions comprising cdk inhibitors and methods for treating cancer: Disclosed herein are compounds suitable for use as antitumor agents, methods for treating cancer wherein the disclosed compounds are used in making a medicament for the treatment of cancer, methods for treating a tumor comprising, administering to a subject a composition comprising one or more of the disclosed cytotoxic agents,... Agent: Georgia State University Research Foundation

20120121691 - Method for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments: A method to improve the effectiveness of cancer treatments by increasing the production of specific ACYL-chain dihydroceramide(s). Increase of native chain-length dihydroceramides is directly cytotoxic to human acute lymphoblastic leukemia cell line MOLT-4 ALL cells with a cytotoxic potency that is dependent upon the specific fatty acid acyl-chain length and... Agent: Texas Tech University System

20120121690 - Method to enhance an immune response of nucleic acid vaccination: A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The... Agent: Lipoxen Technologies Limited

20120121693 - Methods for generating new hair follicles, treating baldness, and hair removal: The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair... Agent:

20120121688 - Preventative or therapeutic agent and method for immune disease: More particularly, the present invention provides a pharmaceutical (e.g., a preventive or therapeutic agent for immune diseases such as allergic disease and autoimmune disease) containing a CD1d ligand and a target antigen (e.g., allergen, autoantigen). Preferably, the pharmaceutical contains a drug delivery vehicle including the CD1d ligand and the target... Agent: Rinken

20120121689 - Small interfering rna delivery: A liposomal siRNA composition is described. The liposomes are formed of neutral liposome forming components, and the composition comprising additionally sugar. The composition provides reduced expression of target gene, without causing systemic toxicity. The composition is produced by a dehydration-rehydration technique to provide high yields and good control of liposome... Agent: Lipoxen Technologies Limited

20120121696 - Terpene glycosides and their combinations as solubilizing agents: Several terpene glycosides (e.g., mogroside V, paenoiflorin, geniposide, rubusoside, rebaudioside A, steviol mono-side and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, celecoxib, clofazimine, digoxin, oleandrin, nifedipine,... Agent:

20120121699 - Lycopene and resveratrol dietary supplement: A dietary supplement is disclosed comprising lycopene and resveratrol in a range of ratio of lycopene:resveratrol from 1:10 to 10:1. Preferably, the ratio is 1:2 to 1:4. Lycopene is preferably of ≧95% purity and resveratrol is of ≧98% purity. Both lycopene and resveratrol may preferably comprise of nano-sized particles in... Agent: Hsiehs Biotech (singapore) Pte Ltd

20120121698 - Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same: The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.... Agent: Amarin Pharma, Inc.

20120121701 - Pharmaceutical composition of peptide drug and enzyme-inhibition compounds: The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject.... Agent:

20120121700 - Pharmaceutical formulations comprising valganciclovir: Pharmaceutical formulations prepared by granulating valganciclovir or a salt thereof, using a nonaqueous solvent or hydro-alcohol.... Agent:

20120121702 - Controlled release azithromycin solid dosage forms: A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.... Agent: Dow Pharmaceutical Sciences, Inc.

20120121703 - Tablet containing ferric citrate: The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer.... Agent: Japan Tobacco Inc.

20120121704 - Aliphatic amine polymer salts for tableting: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater... Agent: Genzyme Corporation

20120121705 - Pharmaceutical or cosmetic or dietetic composition suitable for promoting a hair pigmentation effect: The invention relates to the use of spermidine or a pharmaceutically acceptable derivative thereof as the active principle in a pharmaceutical, cosmetic or dietetic composition. The composition is used for promoting pigmentation of the hair, particularly the shaft of the hair. The invention also relates to the composition which promotes... Agent:

20120121706 - Par-1 activation by metalloproteinase-1 (mmp-1): Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1... Agent: Tufts Medical Center, Inc.

20120121708 - Acetazolamide microparticle and its preparation method and use: A method for preparing an acetazolamide microparticle having a mean particle size ranged between 0.36 μm and 18 μm is provided. The method includes steps of dissolving an acetazolamide in a solvent to form an acetazolamide solution; and mixing the acetazolamide solution with a supercritical fluid at a temperature and... Agent: National Taiwan University

20120121711 - Microsphere drug carrier, preparation method, composition and use thereof: A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH3O—[CH2—CH2—O]m—[C(O)—CH(CH3)—O]n—R... Agent: Xi'an Libang Medical Technology Co., Ltd.

20120121710 - Mucosal immunization: Methods and compositions for eliciting an immune response to an antigen are disclosed. In certain aspects, these methods concern eliciting an immune response in a subject by administering to the mucosa of the subject a composition comprising a virus-like particle (“VLP”) and Murabutide.... Agent: Arizona Board Of Regents For And On Behalf Of Arizona State University

20120121709 - Phase transition biopolymers and methods of use: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site... Agent:

20120121707 - Tolbutamide particle and preparing method thereof and method of reducing a blood glucose: A method for preparing a tolbutamide particle is provided. The method comprises steps of mixing a bulk drug of tolbutamide with a supercritical fluid to form a supercritical mixture; and expanding the supercritical mixture to obtain the tolbutamide particle.... Agent: National Taiwan University

20120121712 - Cellular electric stimulation mediated by piezoelectric nanotubes: Piezoelectric nanotransducers for use in an in vivo treatment of cell stimulation through electrical stimulation are described. The nanotransducers are localized in a target site, and an electrical stimulus is induced in the same site through external stimulation of the nanotransducers by ultrasonic waves.... Agent:

20120121713 - Chimeric therapeutics, compositions, and methods for using same: Chimeric therapeutics are disclosed that include a modified viral core protein comprising at least one mutation or modification in an immunogenic epitope and a therapeutic agent. The therapeutic agent may be associated with the modified viral core protein and may be a nucleic acid, a protein, or a small molecule.... Agent:

20120121714 - Compositions with antigens adsorbed to calcium phosphate: Calcium phosphate is used as an adjuvant, with a high degree of antigen adsorption to the adjuvant. The invention is particularly useful for adjuvanting conjugated capsular saccharide antigens. Buffers, such as phosphate or histidine buffers, can advantageously be used in combination with the calcium phosphate, and compositions may have a... Agent: Novartis Ag

20120121715 - Dna vaccine comprising il-6-encoding dna construct and applications thereof: A DNA vaccine, which comprises a DNA construct comprising an expression vector which is expressible in a eukaryotic cell, and a nucleotide fragment which comprises an IL-6-encoding sequence and an HPV E7(detox)-encoding sequence. A pharmaceutical composition and a method for preventing or treating HPV-related (-induced) diseases are included.... Agent: National Taiwan University

20120121716 - Pharmaceutical composition of an anthracycline: The present invention relates to pharmaceutical composition containing nemorubicin hydrochloride incorporated in microspheres. The compositions are useful for chemoembolisation, particularly for loco regional treatment of tumors.... Agent: Nerviano Medical Sciences S.r.l.

20120121717 - Drug-loaded polysaccharide-coated goldmag particles (dpgps) and its synthesis method: The invention relates to Polysaccharide-coated GoldMag particles (DPGPs) and the method of its synthesis, which characterized GoldMag particles as a core and natural or synthetic biodegradable polysaccharide such as dextran, cyclodextrin and derivatives as shell. DPGPs are synthesized by mixing Polysaccharide-coated GoldMag particles (DPGPs) with drug through physical bond. The... Agent: Xi'an Goldmag Nanobiotech Co. Ltd

20120121718 - Compositions and methods relating to reduced mucoadhesion: The present invention generally relates to reducing the mucoadhesive properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer. Methods for preparing inventive particles using a poly(ethylene glycol)-vitamin E conjugate as a surfactant are also provided. In some... Agent: The Johns Hopkins University

20120121719 - Methods of making and using three-dimensional extracellular matrices: Three-dimensional extracellular matrices lacking synthetic scaffolds are provided. Methods of making the three-dimensional extracellular matrices and methods of using the three-dimensional extracellular matrices are also provided.... Agent: University Of Utah Research Foundation

20120121720 - Modulation of beta 2 adrenergic receptors by inhibitors of egln3 or pvhl: This present invention relates to methods, compositions, and kits useful for treating a patient having or at risk for developing a disorder associated with decreased expression of β2 adrenergic receptors or need for increased 132 adrenergic receptor activity.... Agent:

20120121721 - Skin care products and compositions: Disclosed herein is a composition for treating maladies in humans or animals that includes from about 0.01% to about 40% by weight of a member of the curcuma genus, from about 0.01% to about 40% by weight of a member of the coffea genus and the balance being a pharmaceutically... Agent:

20120121722 - Atazanavir formulations: The present invention relates to formulations comprising atazanavir and a silicate, and the process of preparation thereof, wherein the silicate is present in the extragranular portion.... Agent:

20120121723 - Antimicrobial compositions: An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids,... Agent: Sterilex Technologies, LLC

20120121724 - Film comprising therapeutic agents: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin, as well as other therapeutic agents either with or without nitroglycerin, through the mucosal tissues of the oral cavity. The films include a water soluble... Agent:

20120121725 - Cosmetic composition for the treatment of acne comprising a peptide extract of schizandra: The present invention relates to a cosmetic, nutraceutical or dermatological composition for treating or preventing acne, comprising a peptide and oside extract of Schizandra fruit and a suitable excipient. Preferably, the extract is obtained from Schizandra sphenanthera. The composition may also comprise at least one anti-acne agent selected from a... Agent: Laboratoires Expanscience

20120121726 - Kits and methods for nutrition supplementation: The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids... Agent:

20120121727 - Substituted dihydropyrazolones for treating cardiovascular and hematological diseases: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.... Agent: Bayer Pharma Aktiengesellschaft

20120121728 - Stabilized and activated bromine solutions as a biocide and as an antifouling agent: The invention provides a process of removing or preventing biofouling, particularly on surfaces of industrial and agricultural equipment in contact with aqueous liquids. The process employs an antifouling composition of stabilized active halogen having a low pH.... Agent: Bromine Compounds Ltd.

20120121729 - Antitussive compositions comprising memantine: Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.... Agent:

20120121730 - Pharmaceutical and nutraceutical compositions for treating respiratory disease and associated phlegm: The present invention relates to pharmaceutical compositions comprising dextromethorphan or a physiologically acceptable salt thereof, quercetin, resveratrol, and hesperidin. The invention further relates to nutraceutical or dietary supplement composition comprising a physiologically acceptable salt of magnesium, quercetin, resveratrol, and hesperidin. Further provided are methods for treating respiratory disease in a... Agent: Trinity Laboratories, Inc.

20120121731 - Electrolytic system and method for generating biocides having an electron deficient carrier fluid and chlorine dioxide: A method for electrolytically generating a biocide having an electron deficient carrier fluid and chlorine dioxide, including providing a carrier fluid; providing a pair of electrodes interposed by a semi-permeable membrane within a vessel for creating a first passageway and a second passageway, an anode electrode of the pair of... Agent: Strategic Resource Optimization, Inc.

20120121732 - Composition for use in the prevention and treatment of cardiovascular diseases: The invention provides a composition the prevention and treatment of cardiovascular disease, wherein said composition compounds obtained from palm oil mill effluents, in particular from vegetative liquor from the milling of palm oil fruit.... Agent:

20120121733 - Deodorized edible oil or fat with low levels of bound mcpd and process of making using an inert gas: A process for making a deodorized edible oil or fat having a low level of bound MCPD (monochloro propanediol esters) and/or low level of bound 3-MCPD is described. The process comprises a step of stripping the vegetable oil or fat with an inert gas. The inert gas can be nitrogen.... Agent: Nestec S.a.

20120121735 - Composition and method for reducing food intake: The present invention features compositions and methods for suppressing appetite. The compositions of the invention are composed of a dietary fiber and a combination of selected herbal extracts, at least one of which is capable of inhibiting gastric emptying and one which increases metabolic rate.... Agent: Natures Remedies Ltd.

20120121734 - Compositions containing sucralose and application thereof: Novel utilization of sucralose which is a high intense sweetener. Compositions containing sucralose including: sweetening compositions having excellent sweetness qualities based on the characteristics of sucralose; foods with a masked unpleasant smell and unpleasant taste; performance food compositions (viscous food compositions, gel food compositions, emulsified food compositions); foods with improved... Agent: San-ei Gen F.f.i., Inc.

20120121736 - Composition for treating gastric ulcer and a process thereof: The present invention relates to a herbal composition for treating gastric ulcer, a method for preparing said herbal composition.... Agent:

20120121737 - Compositions comprising trans-tert-butyl cyclohexanol as skin irritation-reducing agent: The present invention primarily relates to the use of trans-tert-butyl cyclohexanol as skin irritation-reducing agent as well as compositions (formulations) having a skin irritation-reducing action comprising trans-tert-butyl cyclohexanol as skin irritation-reducing agent.... Agent: Symrise Ag

20120121738 - Bioactive botanical cosmetic compositions and processes for their production: The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin... Agent: Akzo Nobel Surface Chemistry LLC

20120121739 - Bioactive botanical cosmetic compositions and processes for their production: The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin... Agent: Akzo Nobel Surface Chemistry LLC

20120121740 - Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occurring age related erectile dysfunction: Compositions for treating erectile dysfunction (“ED”), including age related erectile dysfunction (ARED), comprise in a preferred embodiment ginger and an amino acid. Preferably the amino acid is L-arginine and/or L-citrulline. Additionally, the compositions may comprise guarana (Paullinia cupana), Muira puama cortex magnoliae officinalis (CMO) and/or fructus aurantil immaturus (FAI). The... Agent: K.l.r.m., LLC

20120121741 - Water soluble defructosylated pea extract, and use thereof as a prebiotic agent: The present invention relates to a water-soluble defructosylated pea extract, substantially free of proteins and peptides, as well as to an oligosaccharide composition such as that contained in said extract. It also relates to the method for preparing the same, and to the use thereof as a prebiotic agent.... Agent:

20120121742 - Plant extracts for use as phytochemicals: The invention concerns the use of grape (Vitis vinifera) seeds extracts as agents for the treatment and prevention of plant diseases caused by pathogens, particularly by fungi and oomycetes, as well as fungicidal compositions comprising Vitis vinifera extracts for application to plants affected or liable to be affected by a... Agent: Indena S.p.a.

20120121743 - Schisandra sphenanthera fruit extract and cosmetic, dermatological and nutraceutical compositions comprising same: The present invention relates to a cosmetic, dermatological or nutraceutical composition comprising a Schisandra sphenanthera fruit extract. Said Schisandra sphenanthera fruit extract is selected from a peptide and sugar extract, a crude oil, a refined oil, a refined oil concentrate or the unsaponifiable fraction of said concentrate. The invention also... Agent:

20120121745 - Agents for the control of limnoperna sp.: Compositions and methods for controlling Limnoperna sp., particularly, golden mussels are provided using Pseudomonas sp. suspension or compounds and compositions derived from said suspension.... Agent: Marrone Bio Innovations, Inc.

20120121744 - Pharmaceutical composition for inhibiting infection and replication of influenza a and b virus, and the manufacture thereof: Disclosed is a pharmaceutical composition for inhibiting infection and replication of influenza A and B virus, and the manufacture thereof. The pharmaceutical composition is produced by a manufacture of low-temperature disintegrating cyanobacteria, comprising the steps of: (a) mixing cyanobacteria and non-organic solvent to form a suspension containing cyanobacteria; (b) freezing... Agent: Far East Bio-tec Co., Ltd.